Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

• DOI: 10.1007/s10637-015-0226-6
• Publication Date: 2015-03-30T07:48:25Z
• Authors: David S. Hong; Filip Janku; Aung Naing; Gerald S. Falchook; Sarina Piha-Paul; Jennifer J. Wheler; Siqing Fu; Apostolia M. Tsim...; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
• Keywords: Adult; Aged, 80 and over; Male; Lung Neoplasms; Body Weight; Antibodies, Monoclonal; Antineoplastic Agents; Kaplan-Meier Estimate; Middle Aged; Antibodies, Monoclonal, Humanized; Antibodies; Disease-Free Survival; 3. Good health; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Interleukin-1alpha; Humans; Female; Inflammation Mediators; Energy Metabolism; Aged

Advanced non-small cell lung cancer (NSCLC) patients were treated as part of a Phase I dose escalation and expansion study evaluating a true human monoclonal antibody targeting IL-1α (Xilonix), which is intended to modulate the malignant phenotype-inhibiting tumor growth, spread and offering relief of symptoms.Sixteen NSCLC patients were included. Patients failed a median of 4 chemotherapy regimens, including 10/16 failing anti-EGFR therapy. Disease progression was evaluated using a multi-modal approach: tumor response, patient reported outcomes (EORTC-QLQC30), and lean body mass (LBM). Patients received infusions every 2 or 3 weeks until progression, and were followed 24 months to assess survival.There were no infusion reactions, dose-limiting toxicities, or deaths due to therapy. Albeit not statistically significant, there was a trend in IL-6 (-2.6 ± 18.5 (0.1 [-2.8-2.4]), platelet counts (-11 ± 54 (-4[-36.0-1.0]), CRP (-3.3 ± 30.2 (0.4 [-10.7-1.8]) and LBM (1.0 ± 2.5 (0.4 [-0.5-2.6]). Self-reported outcomes revealed reductions in pain, fatigue and improvement in appetite. Median survival was 7.6 (IQR 4.4-11.5) months, stratification based on prior anti-EGFR therapy revealed a median survival of 9.4 months (IQR 7.6-12.5) for those pretreated (N = 10) versus a survival of 4.8 months (IQR 4.3-5.7) for those without (N = 6, logrank p = 0.187).Xilonix was well tolerated, with gains in LBM and improvement in symptoms suggesting a clinically important response. Although not statistically significant, the survival outcomes observed for patients with and without prior anti-EGFR therapy raises intriguing questions about the potential synergy of IL-1α blockade and anti-EGFR therapy. Further study for this agent in NSCLC is warranted.